Development of novel therapies for Huntington's disease: hope and challenge1

Authors

  • Zheng-hong QIN,

    Corresponding author
    1. Department of Pharmacology, Soochow University School of Medicine, Suzhou 215007, China;
    2. Laboratory of Cellular Neurobiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA;
      Correspondence to Zheng-hong QIN, PhD.
      Phn 86-512-6512-2087.
      Fax 86-512-6519-0599.
      E-mail zhqin5@hotmail.com
    Search for more papers by this author
  • Jin WANG,

    1. Molecular Neurogenetics Unit, Center for Human Genetics Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Search for more papers by this author
  • Zhen-lun GU

    1. Department of Pharmacology, Soochow University School of Medicine, Suzhou 215007, China;
    Search for more papers by this author

  • 1

    Supported by the National Natural Science Foundation of China (No 30370506).

Correspondence to Zheng-hong QIN, PhD.
Phn 86-512-6512-2087.
Fax 86-512-6519-0599.
E-mail zhqin5@hotmail.com

Abstract

Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5–10 out of 10 000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.

Ancillary